About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 1

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

A Single-dose, Open-label, Pharmacokinetic Study of KD025 in Subjects With Normal Hepatic Function & Subjects With Varying Degrees of Hepatic Impairment

NCT04166942•Kadmon, a Sanofi Company

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Hepatic Impairment

Interventions

KD025

Locations

5

United States

Locations (5)

Inland Empire Clinical Trials, LLC-HQ

Rialto, California, United States

Clinical Pharmacology of Miami

Miami, Florida, United States

Advanced Pharma CR, LLC

Miami, Florida, United States

Omega Research Group

Orlando, Florida, United States

The Liver Institute

San Antonio, Texas, United States

Key Dates

Start Date

December 11, 2019

Primary Completion Date

June 6, 2022

Completion Date

June 6, 2022

Last Updated

July 18, 2022

Related Studies

RECRUITINGPhase 1

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

NCT07324616

Hepatic Impairment (HI)

RECRUITINGPhase 1

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

NCT04271488

Hepatic Impairment

RECRUITINGPhase 1

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

NCT06952634

Hepatic Impairment

COMPLETEDPhase 1

A Varegacestat Hepatic Impairment Study

NCT06841315

Healthy VolunteerHepatic Impairment (HI)

COMPLETEDPhase 1

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001

NCT06619054

Healthy AdultsHepatic Impairment

COMPLETEDPhase 1

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

NCT06813781

Hepatic Impairment

View all related studies

Sponsors

Lead Sponsor

Kadmon, a Sanofi Company

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 18, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions